



Date 17 November 2016

Sydney, Australia

## MEDICAL ADVISORS APPOINTED TO SUPPORT EXTENSIVE CLINICAL PROGRAM

Noxopharm Limited (ASX: NOX) confirms a number of key medical appointments as part of the Company's initiation of its clinical trials program.

Professor Paul de Souza has been appointed as Medical Advisor. Professor de Souza holds the Foundation Chair in Medical Oncology, School of Medicine, Western Sydney University. He formally will advise the Company on both its clinical trial and drug development strategies, plus chair the Company's Medical Advisory Panel. The position is part-time. Professor de Souza has considerable experience with the Company's core technologies, having conducted the first Phase 1b clinical study of idronoxil as well as a number of laboratory studies.

Associate Professor Thomas Eade and Associate Professor George Hruby have been appointed as radiation oncology consultants. Both hold senior staff positions at Royal North Shore Hospital, Sydney, and clinical academic positions in the Faculty of Medicine, The University of Sydney.

The appointments come as Noxopharm is about to begin recruitment into its first clinical study of NOX66 as part of a clinical program expected to involve up to 5 Phase 1b studies over the next 12 months. This program is designed to provide proof-of-concept clinical data within the next 12 months on the ability of NOX66 to deliver meaningful clinical responses of late-stage cancers to low, well-tolerated dosages of chemotherapy and radiotherapy. The cancers being tested involve prostate, breast, ovary, lung and head & neck carcinomas.

Dr Kelly, Noxopharm CEO, said, "These 3 appointments are the foundations for our clinical efforts over the next couple of years. We wanted advisors who will be active participants in the development of NOX66, including running some of our clinical studies, and not just advising from a distance. A proposed program of 5 clinical studies is a considerable undertaking that will require the backing of an experienced Advisory Panel comprising Australian medical oncologists and radiation oncologists, most of whom who will be active participants in the clinical program."

**ASX: NOX**

**Noxopharm Limited**

ABN 50 608 966 123

**Registered Office:**

Suite 1 Level 6

50 Queen St

Melbourne VIC 3000

Australia

**Board of Directors**

**Mr Peter Marks**

Chairman

Non-Executive

Director

**Dr Graham Kelly**

Chief Executive Officer

Managing Director

**Dr Ian Dixon**

Non-Executive

Director

### **About Professor Paul de Souza** BScMed MB BS MPH PhD FRACP

Professor **Paul de Souza** is Foundation Professor of Medical Oncology at Western Sydney University, a practicing medical oncologist at Liverpool Hospital, a conjoint Professor in the Faculty of Medicine, University of NSW, and an Honorary Professor of the NHMRC Clinical Trials Centre, The University of Sydney. After completion of his Medical Oncology training and awarded a Fellowship of the Royal Australasian College of Physicians, Paul was appointed as a Research Associate and later, an Assistant Professor of Medicine at the University of Virginia where he developed his clinical and research interests in cancer drug development. Paul completed his PhD in novel drug development at UNSW Australia. Paul's diverse repertoire in all aspects of Medical Oncology includes management and administration, clinical work, research, supervision, and teaching. Paul has been a principal clinical investigator for over 40 clinical trials, specialising in all aspects of clinical trials from Phase I to IV. His research interests include: (i) translational drug development in cancer (preclinical to early Phase clinical trials of novel treatments), (ii) signal transduction and mechanisms of drug resistance, (iii) urological cancers, including renal, bladder and prostate cancer, and neurological cancers, especially glioblastoma multiforme, and (iv) quality of life in cancer patients.

### **About Associate Professor Thomas Eade** MB ChB FRANZCR

A/Prof Thomas Eade is Director of of Research in Radiation Oncology at the Northern Sydney Cancer Centre (NSCC) at Royal North Shore Hospital, Sydney. He took up this post in 2007 after time spent working as the Thomas Baker Fellow at the Fox Chase Cancer Center in Philadelphia, USA. Fox Chase is one of the leading specialist centres to treat prostate cancer in the USA. A/Prof Eade trained in the latest radiation therapy techniques including IMRT, intra-operative real-time seed brachytherapy and high dose rate brachytherapy.

Recognized across the country for his expertise in the IMRT/VMAT and IGRT techniques for the treatment of prostate cancer, he has led the way for the NSCC to become one of the leading prostate cancer radiation treatment centres in Australia and he has been a guest speaker at state, national and international meetings on advanced radiation techniques.

In addition to his strong patient care and outcome focus, A/Prof Eade is also a committed researcher and has published in major international oncology journals. He also developed the prospective database for prostate cancer radiotherapy, which is in use across the North Shore and Central Coast campuses. A key area of interest for him is in researching and evaluating the delivery of new technology in radiotherapy. He is the Principle Investigator for the first Australian study of Stereotactic Radiotherapy for prostate cancer.

### **About Associate Professor George Hruby** BHB MB ChB FRANZCR

A/Prof Hruby is Senior Staff Specialist in radiation Oncology at Royal North Shore Hospital, Sydney and Associate Professor at The University of Sydney. Following a fellowship at the Royal Prince Alfred Hospital in 1999, he was awarded a clinical fellowship at the University of Toronto. This role focused on genito-urinary cancers, including training in prostate brachytherapy.

In Dec 2000 he commenced as Staff Specialist in Radiation Oncology at the Royal Prince Alfred Hospital, working also at Concord and Dubbo hospitals. Specialisations included genito-

For personal use only

urinary and gastro-intestinal malignancies as well as melanoma and merkel cell carcinoma. He has also established a close working relationship with the urologists in Noumea and has treated many New Caledonian men with prostate cancer over the years.

A/Prof Hruby established the High Dose Rate brachytherapy program at Royal Prince Alfred Hospital with over 300 implants performed since inception in 2002. He was instrumental in introducing image guided radiation treatment (IGRT) in 2007 and IMRT in 2009 for the treatment of prostate cancer at RPAH.

A/Prof Hruby's aim is always to optimally and compassionately manage the patient. An extension of this is to audit and research results so doctors and patients may better understand the implications of their treatment. George has been heavily involved in local, national and international trials and is an active participant in TROG and ANZUP. He is an advocate of radiation oncology, and is often called upon to speak at conferences, prostate cancer forums or to teach colleagues. George has also co-authored over 70 peer reviewed publications.

#### **About Noxopharm**

Noxopharm is an Australian drug development company with offices in Melbourne and Sydney. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development in an R&D program.

#### **About The Phase 1 Clinical Trial Program**

Noxopharm is pursuing the development of NOX66 as an adjunct therapy for both chemotherapy and radiotherapy, particularly with a view to sensitising cancer cells to the extent that low dosages of chemotherapy or radiotherapy will be sufficient to produce meaningful clinical responses where no response would be anticipated. The program is designed to test NOX66 across a range of cancer types and under differing treatment regimens with the objective of providing in a timely manner proof-of-concept and guidance for registration studies. The studies involve patients with late-stage cancers for whom there are no remaining standard therapeutic options, are open studies, and involve 10-15 patients. The program includes both industry-sponsored studies and investigator-initiated studies.

#### **About NOX66**

NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to protect idronoxil from being inactivated in the human body by Phase 2 metabolism. Its purpose is to ensure that most idronoxil administered remains in an active form. Idronoxil works by cancelling pro-survival mechanisms in cancer cells regulated by sphingosine-1-phosphate that allow the cells to resist the killing effects of chemotherapies and radiotherapy.

#### **INVESTOR AND MEDIA ENQUIRIES:**

**E: [info@noxopharm.com](mailto:info@noxopharm.com)**

**Prue Kelly**

**T: + 61 2 9144 2223**

#### **Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements

For personal use only

to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.